Penn prof weighs in on 'desktop medicine'

Monday, December 6, 2010 - 1:00am

Jason Karlawish was interviewed for an article in The New York Times about desktop medicine, a medical model based on risk analysis. According to Dr. Karlawish, desktop medicine features “clinical actuarial correlation” —  statistical models in which doctors can collect information from patients based on their history and clinical tests in order to predict a patient’s risk of developing a certain condition. In this manner, risk becomes disease and medicine...

Learn More



Money Woes Can Be Early Clue to Alzheimer’s

Sunday, October 31, 2010 - 12:00am

In an interview with the New York Times about money troubles in patients with Alzheimer's disease, Jason Karlawish, MD, an associate professor of Medicine and Medical Ethics as well as Associate Director of and a practicing clinician in the Penn Memory Center, says it is generally agreed that decisions by a competent adult should be respected. But, he said, “What do we mean when we say someone has enough decision-making capacity to be ‘competent’? The law, psychology and...

Learn More



New Developments in the Battle Against Alzheimer's

Monday, October 25, 2010 - 12:00am

Five million Americans suffer from Alzheimer’s disease and that number is expected to grow considerably with the aging population. But there is some good news. Recently there have been some promising new developments that could lead to advances in the diagnosis and the treatment of the disease. WHYY's Radio Times sits down with two Alzheimer’s researchers to talk about the latest developments in the field: John Trojanowski, MD, PhD, Professor of Geriatric Medicine and...

Learn More



When Drugs Cause Problems They Are Supposed To Prevent

Saturday, October 16, 2010 - 12:00am

In the past month, the Food and Drug Administration has concluded that in some cases two types of drugs that were supposed to be preventing serious medical problems were, in fact, causing them, reports the New York Times. Jason Karlawish, MD, an associate professor of Medicine and Senior Fellow of the Center for Bioethics, who studies the ways new treatments are developed and disseminated, expressed a similar concern. “The point is not that the drugs are bad, but that...

Learn More

Syndicate content